Kidney with renal cell carcinoma being treated with a cryoablation needle

EuRECA Registry

Cryoablation in RCC

Clinical Evidence Supporting Cryoablation in RCC: The EuRECA Registry

A joint mission between Urologists and Interventional Radiologists 

Largest real-world, prospective, multicenter, multidisciplinary study
on the use of cryoablation for treatment of RCC in 1700+ patients1

EuRECA Registry studied the use of cryoablation for treatment of RCC in 1700+ patients

1700+ RCC patients,
1400+ biopsy-confirmed

EuRECA Registry was carried out over 14 sites across 5 European cities

14 sites across
5 European countries

EuRECA Registry studied disease-free recurrence, overall survival and more

Studying disease-free recurrence,
overall survival, and more

The EuRECA registry demonstrates cryoablation is a safe and effective RCC treatment with durable long-term oncologic outcomes.

Primary technical efficacy2

97.9%

T1a tumours

94.1%

T1b tumours

CT-guided, biopsy-proven T1a3

1.6%

Low major complication rate

96.1%

5-year local recurrence-free survival

Renal function preserved, including in patients with solitary kidney4,5

Explore  EuRECA data presented at  CIRSE 2026

Dr.  Alex King

EuRECA  evidence on safety, renal function, hereditary RCC, and residual disease6

Watch full video

Prof. ole graumann

5-year oncologic outcomes following CT-guided cryoablation of biopsy-proven T1a RCC7

Watch full video

Cryoablation is a safe and effective treatment for patients with RCC2,3

Of 1,207 patients with T1a RCC, cryoablation showed an overall primary technical efficacy (PTE) of 97.9%2

  • The most significant risk factor for residual untreated tumour (RUT) is central renal vessel contact
  • T1b PTE: 94.1%

Among 757 CT-guided T1a patients, cryoablation demonstrated a low major complication rate of 1.6%3

Major complication rate for this study is defined as Clavien Dindo grade ≥ 3

Cryoablation preserved renal function while minimizing the risk of progression to chronic kidney disease or the need for dialysis in patients with a solitary kidney and RCC4,5

In two studies – one using laparoscopy-assisted renal cryoablation (LARC) and the other percutaneous cryoablation – all patients had solitary kidneys, yet none required dialysis, and no patients with chronic kidney disease advanced to severe or end-stage (IV or V). ​

  • 72 patients underwent LARC and 70 patients underwent percutaneous cryoablation
  • LARC treatments resulted in eGFR reduction of 6.8%
  • Percutaneous cryoablation treatments resulted in eGFR reduction of 11.1%​

Cryoablation demonstrated durable long-term oncologic outcomes3

Favorable long-term oncologic outcomes following CT-guided cryoablation in 757 patients with biopsy-proven T1a RCC

96.1%

Local recurrence-free survival

97.6%

Metastasis-free survival

99.2%

Cancer-specific survival

5-year median follow-up; mean tumour size 2.7 cm

icon-person-with-headset

Contact a sales representative

Do you have questions? Want to learn more about our products and services?

Request a sales representative
icon-document-with-magnifying-glass

View all products

Discover our best-in-class interventional oncology and embolisation portfolio.

Browse all products
Icon representing get updates

Stay up-to-date

Receive emails about the latest interventional oncology news, innovations and events.

Sign up for updates

References

  1. EuRECACryotherapy Registry, https://www.eureca-registry.com/Public/Home.aspx 
  2. King, A. J., Steenkamp, R., Graumann, O., Wah, T. M., Alcorn, D., Nielsen, T. K., de Kerviler, E., Zondervan, P. J., Walkden, M., Lagerveld, B., Van Strijen, M., Keeley Jr., F. X., & Breen, D. J. (2025). Risk Factors for Residual Unablated TumourFollowing CT-Guided Percutaneous Renal Cryoablation: Lessons from the EuRECARegistry. CardioVascularand Interventional Radiology, 48(2), 196-204. Article 802437. https://doi.org/10.1007/s00270-024-03951-2
  3. Graumann O, Nielsen TK, AlcronD, et al. CT-guided Cryoablation for Biopsy-proven T1a Renal Cell Carcinoma: Long-term Oncological Outcomes from the Prospective Multinational EuRECARegistry. Scientific presentation abstract presented at: CIRSE 2026; September 6, 2026.
  4. Pietersen, P. I., Stougaard, S., Keeley, F. X., Jr, Lagerveld, B., Breen, D., King, A., Nielsen, T. K., van Strijen, M., Garnon, J., Alcorn, D., de Kerviler, E., Zondervan, P., Wah, T. M., Junker, T., & Graumann, O. (2024). Renal Function After CT-Guided Cryoablation of Small Renal Tumoursin Patients with Solitary Kidney: An Analysis of European Multinational Prospective EuRECARegistry. Cardiovascular and interventional radiology, 47(5), 583–589. https://doi.org/10.1007/s00270-023-03634-4
  5. Sriprasad, S., Aldiwani, M., Pandian, S., Nielsen, T. K., Ismail, M., Barber, N. J., Lughezzani, G., Larcher, A., Lagerveld, B. W., & Keeley, F. X., Jr (2020). Renal Function Loss After Cryoablation of Small Renal Masses in Solitary Kidneys: European Registry for Renal Cryoablation Multi-Institutional Study. Journal of endourology, 34(2), 233–239. https://doi.org/10.1089/end.2019.0669
  6. King A. EuRECApublications: what we've learned so far. Presented at: Boston Scientific Industry-Sponsored Symposium, CIRSE 2026; September 7,2026; Copenhagen, Denmark.
  7. Graumann O. First look at the new EuRECAlong-term oncologic outcomes. Presented at: Boston Scientific Industry-Sponsored Symposium, CIRSE 2026; September 7, 2026; Copenhagen, Denmark.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.